- Home
- PMCB vs KLTO Comparison
PMCB vs KLTO Comparison
Compare PMCB & KLTO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PMCB
- KLTO
- Stock Information
- Founded
- PMCB 1996
- KLTO 2019
- Country
- PMCB United States
- KLTO United States
- Employees
- PMCB N/A
- KLTO N/A
- Industry
- PMCB Biotechnology: Biological Products (No Diagnostic Substances)
- KLTO
- Sector
- PMCB Health Care
- KLTO
- Exchange
- PMCB Nasdaq
- KLTO NYSE
- Market Cap
- PMCB 7.3M
- KLTO 5.9M
- IPO Year
- PMCB N/A
- KLTO N/A
- Fundamental
- Price
- PMCB $1.10
- KLTO $1.33
- Analyst Decision
- PMCB
- KLTO
- Analyst Count
- PMCB 0
- KLTO 0
- Target Price
- PMCB N/A
- KLTO N/A
- AVG Volume (30 Days)
- PMCB 11.9K
- KLTO 92.2M
- Earning Date
- PMCB 08-12-2025
- KLTO 08-15-2025
- Dividend Yield
- PMCB N/A
- KLTO N/A
- EPS Growth
- PMCB N/A
- KLTO N/A
- EPS
- PMCB 1.29
- KLTO N/A
- Revenue
- PMCB N/A
- KLTO N/A
- Revenue This Year
- PMCB N/A
- KLTO N/A
- Revenue Next Year
- PMCB N/A
- KLTO N/A
- P/E Ratio
- PMCB $0.86
- KLTO N/A
- Revenue Growth
- PMCB N/A
- KLTO N/A
- 52 Week Low
- PMCB $1.00
- KLTO $0.11
- 52 Week High
- PMCB $2.42
- KLTO $3.91
- Technical
- Relative Strength Index (RSI)
- PMCB 53.12
- KLTO N/A
- Support Level
- PMCB $1.00
- KLTO N/A
- Resistance Level
- PMCB $1.07
- KLTO N/A
- Average True Range (ATR)
- PMCB 0.05
- KLTO 0.00
- MACD
- PMCB 0.01
- KLTO 0.00
- Stochastic Oscillator
- PMCB 66.67
- KLTO 0.00
About PMCB PharmaCyte Biotech Inc.
PharmaCyte Biotech Inc is a clinical-stage biotechnology company. The company is focused on developing and preparing to commercialize cellular therapies for cancer and diabetes based on a proprietary cellulose-based live cell encapsulation technology called Cell-in-a-Box. The Cell-in-a-Box technology is intended to be used as a platform upon which therapies for several types of cancer, including inoperable pancreatic cancer, and diabetes will be developed. The company is developing therapies for the pancreas and other solid cancerous tumors involving the encapsulation of live cells placed in the body to enable the delivery of cancer-killing drugs at the source of cancer.
About KLTO KLOTHO NEUROSCIENCES INC
Klotho Neurosciences Inc is in the development of essential medicines for the treatment of chronic diseases: Cancer, Cardiovascular, and Neurodegenerative disorders. The Company currently has acquired two licensed platforms: a generic drug portfolio and a biosimilar biologics platform that uses biologic therapies to treat cancer, and a proprietary, patented gene therapy platform which uses a gene therapy approach to introduce a therapeutic protein called Klotho inside the body to treat neurodegenerative diseases. Company pipeline includes KLTO 101, KLTO 202, KLTO 301.